Related Experiment Video
Updated: Aug 24, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
[Treatment of insulin-dependent diabetes: new therapy by electromagnetic replacement: towards an artificial pancreas]
Jacques Bringer1, Guy Costalat, Claude Jaffiol
1CHU Hôpital Lapeyronie, 371 avenue du doyen Gaston Géraud-34295 Montpellier.
Abstract:
The goal of treatment of diabetes mellitus is the achievement of sustained normoglycemia to prevent the complications with the lowest incidence of hypoglycemia. In the same time, it attempts to reduce the hourly and daily constraints due to multiple injections and self monitoring of glycemia. Both intermittent injections and subcutaneous route are inappropriated to extreme precision and flexibility of regulation requested to reach optimal glycemic control and the best quality of life in most diabetic people. The progress in biomaterials and micro-electronics, the availability of stable insulin solutions have permitted to implant a pump with an awaited functional autonomy for 10 years and to perfuse insulin by peritoneal way in a continuous and modulable fashion. The intra-vascular implanted enzymatic glucose sensors, using glucose-oxidase, are able to measure with good accuracy real-time blood glucose for the duration from 6 to 12 months. The combination of these two linked devices implanted in type 1 diabetic patients has given the opportunity to perform the first trials for periods of 48 hours delivering automated insulin according to glycemic variability. This most physiological restoration of insulin function is feasible and appears to represent a possibility for long term treatment of diabetics.
Related Concept Videos
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Type I Diabetes I: Introduction
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Introduction
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
